Benzinga's Top #PreMarket Gainers

shares rose 25.44 percent to $7.20 in pre-market trading after the company reported top-line results from Multicenter Phase 2 Portal Hypertension clinical trial in patients with liver cirrhosis.

shares rose 22.55 percent to $8.26 in pre-market trading following announcement of results of ARC-520 Hep B study.

shares climbed 19.64 percent to $4.69 in pre-market trading following announcement of the EU approval for Fexericx for the treatment of hyperphosphatemia in adults with chronic kidney disease.

gained 2.97 percent to $5.55 in pre-market trading after jumping 25.06 percent on Wednesday.

shares rose 1.62 percent to $15.05 in pre-market trading after dropping 3.89 percent on Wednesday.